Patents Assigned to The United States of America as represented by the Secretary of the Department of Health and Human Services
  • Anti-flavivirus compounds and methods of use
    Patent number: 11471443
    Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: October 18, 2022
    Assignees: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC., The United States of America, as represented by the Secretary, Department of Health and Human Service, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
  • SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE BETA
    Publication number: 20220325266
    Abstract: Synthetic polynucleotides encoding human propionyl-CoA carboxylase beta (synPCCB) and exhibiting augmented expression in cell culture and/or in a subject are described herein. An adeno-associated viral (AAV) gene therapy vector encoding synPCCB successfully rescued the neonatal lethal phenotype displayed by propionyl-CoA carboxylase beta (Pccb?/?) deficient mice, lowered circulating methylcitrate levels in the treated animals, and resulted in prolonged hepatic expression of the product of the synPCCB transgene in vivo.
    Type: Application
    Filed: October 15, 2020
    Publication date: October 13, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Charles P. Venditti, Randy J. Chandler
  • Water soluble novel cyanine fluorophore with tunable properties between near IR and SWIR region for in vivo imaging
    Patent number: 11465993
    Abstract: Cyanine fluorophores including a nine-carbon polymethine bridge are disclosed. The cyanine fluorophores have absorbance and/or emission maxima in the near-infrared (NIR) and short-wave infrared (SWIR) wavelength ranges. Methods of making and using the cyanine fluorophores are also disclosed. The compounds are useful in fluorescence imaging, more particularly in cancer treatment.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: October 11, 2022
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Martin J. Schnermann, Venu G. Bandi
  • immunogenic compositions
    Patent number: 11464845
    Abstract: Immunogenic compositions are disclosed that include Neisseria meningitidis microvesicles, such as outer membrane vesicles (OMV) and/or blebs, from PorA?PorB? Neisseria, such as PorA?PorB?RmpM? Neisseria meningitidis. These immunogenic compositions are of use to induce an immune response to Neisseria, including Neisseria meningitidis and Neisseria gonorrhea.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: October 11, 2022
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Margaret Bash, Kathryn Matthias
  • HLA class I-restricted t cell receptors against mutated RAS
    Patent number: 11466071
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: October 11, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rami Yoseph, Yong-Chen Lu, Gal Cafri, Steven A. Rosenberg
  • Imaging and diagnostic methods, systems, and computer-readable media
    Patent number: 11464413
    Abstract: One aspect of the present subject matter provides an imaging method including: receiving a trigger signal; after a period substantially equal to a trigger delay minus an inversion delay, applying a non-selective inversion radiofrequency pulse to a region of interest followed by a slice-selective reinversion radiofrequency pulse to a slice of the region of interest of a subject; and after lapse of the trigger delay commenced at the cardiac cycle signal, acquiring a plurality of time-resolved images of the slice of the region of interest from an imaging device.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: October 11, 2022
    Assignee: The United States of America as represented by Secretary, Department of Health and Human Services
    Inventors: Khaled Z. Abd-Elmoniem, Ahmed M. Gharib, Roderic I. Pettigrew
  • Compositions and methods for treating cancer with anti-CD33 immunotherapy
    Patent number: 11464801
    Abstract: Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: October 11, 2022
    Assignees: LENTIGEN TECHNOLOGY, INC., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Detection of blaantibacterial resistance genes
    Patent number: 11466329
    Abstract: Methods and compositions are provided for the detection of BlaIMP. The disclosed methods and compositions can detect all known IMP variants in a single, rapid assay.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: October 11, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Linda Maria Erika Karlsson, Davina Elaine Campbell
  • GRIFFITHSIN MUTANTS
    Publication number: 20220315629
    Abstract: The invention provides modified griffithsin polypeptides comprising the amino acid sequence of SEQ ID NO: 1, as well as corresponding nucleic acids, vectors, cells, fusion proteins, constructs, conjugates, and methods of inhibiting viral infection.
    Type: Application
    Filed: April 19, 2022
    Publication date: October 6, 2022
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, University of Louisville Research Foundation, Inc., University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Barry R. O'Keefe, Tinoush Moulaei, Kenneth E. Palmer, Lisa C. Rohan, Joshua L. Fuqua, Lindsay F. Kramzer
  • BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USE
    Publication number: 20220313801
    Abstract: Brachyury protein can be used to induce Brachyury-specific CD4+ T cells in vivo and ex vivo. It is also disclosed that Brachyury protein can be used to stimulate the production of both Brachyury-specific CD4+ T cells and Brachyury-specific CD8+ T cells in a subject, such as a subject with cancer. In some embodiments, the methods include the administration of a Brachyury protein. In additional embodiments, the methods include the administration of a nucleic acid encoding the Brachyury protein, such as in a non-pox non-yeast vector. In further embodiments, the methods include the administration of host cells expressing the Brachyury protein.
    Type: Application
    Filed: June 6, 2022
    Publication date: October 6, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Jeffrey Schlom, Claudia M. Palena
  • 3D vascularized human ocular tissue for cell therapy and drug discovery
    Patent number: 11458225
    Abstract: Methods are disclosed for fabricating a three-dimensional engineered blood retinal barrier (BRB) comprising a choroid and retinal pigment epithelial cells. The methods include the use of bioprinting. Also disclosed is a three-dimensional engineered BRB, and its use. Methods are also disclosed for using the three-dimensional engineered BRB, such as for the treatment of retinal degeneration in a subject or screening. A three-dimensional printing insert that is adapted for bioprinting on a culture substrate sheet that is securely retained within and exposed through a printing frame is also disclosed.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 4, 2022
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kapil Bharti, Min Jae Song, Russell Louis Quinn
  • Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type A receptors as fast acting treatment for depression and mood disorders
    Patent number: 11459320
    Abstract: The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: October 4, 2022
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Scott Thompson, Adam Van Dyke, Craig Thomas, Patrick Morris
  • Recombinant HIV-1 envelope proteins and their use
    Patent number: 11459360
    Abstract: HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: October 4, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Kwong, Marie Pancera, Tongqing Zhou, Ivelin Georgiev, Michael Gordon Joyce, Priyamvada Acharya, Jason Gorman, Yongping Yang, Guillaume Stewart-Jones, Rita Chen, Gwo-Yu Chuang, John Mascola, Baoshan Zhang, Cheng Cheng, Mallika Sastry, Aliaksandr Druz
  • Compositions and methods for treating cancer with anti-ROR1 immunotherapy
    Patent number: 11453719
    Abstract: Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: September 27, 2022
    Assignees: LENTIGEN TECHNOLOGY, INC., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Synthetic bright-blood and dark-blood PSIR LGE images
    Patent number: 11454691
    Abstract: Systems and methods to determine a first map of a first parameter based on first signals acquired by a magnetic resonance imaging system, the first map associating each of a plurality of voxels with a respective value of the first parameter, the first parameter quantifying a first physical characteristic of an object represented by the plurality of voxels, determine a second map of a second parameter based on the first signals, the second map associating each of the plurality of voxels with a respective value of the second parameter, the second parameter quantifying a second physical characteristic of the object, and determine a dark-blood phase-sensitive inversion recovery late gadolinium enhancement image based on the first map of the first parameter and on the second map of the second parameter.
    Type: Grant
    Filed: September 13, 2021
    Date of Patent: September 27, 2022
    Assignees: Siemens Healthcare GmbH, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Kellman, Hui Xue, Kelvin Chow
  • Systems and methods for conducting contact-free thickness and refractive-index measurements of intraocular lenses using a self-calibrating dual confocal microscopy
    Patent number: 11454794
    Abstract: Systems and methods for conducting contact-free thickness and refractive-index measurements of transparent objects, such as intraocular lenses using a dual confocal microscopy system are disclosed.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: September 27, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Do-Hyun Kim, Ilko Kolev Ilev, Robert Harold James, Don Calogero
  • Injectable dendrimer hydrogel nanoparticles
    Patent number: 11446238
    Abstract: Injectable hydrogels in the form of crosslinked nano beads or particle in the size range 5 nm to 10 ?m, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents are formed by reaction of the PAMAM dendrimer with asymmetrical end groups with linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel is formed as small crosslinked particles in the size range 25 nm to 10 ?m and is suitable for injectable delivery of hydrogel or ocular delivery for the purpose of therapeutic treatment and imaging.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: September 20, 2022
    Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Kannan Rangaramanujam, Sujatha Kannan, Roberto Romero, Raghavendra Navath, Anupa Menjoge
  • AAV with unique capsid protein VP1 and methods of using for treatment
    Patent number: 11447797
    Abstract: The invention provides an adeno-associated viral (AAV) vector comprising a capsid comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 9, wherein the AAV vector further comprises a heterologous nucleic acid sequence, and wherein the heterologous nucleic acid sequence can encode the NGF-PTH fusion polypeptide or methylmalonyl CoA mutase enzyme. The invention also provides a polypeptide comprising nerve growth factor (NGF) signal peptide and parathyroid hormone (PTH), wherein the polypeptide can comprise, consist essentially of, or consist of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2. The invention provides a nucleic acid encoding the polypeptide, a vector comprising the nucleic acid, and a composition comprising the polypeptide, nucleic acid, or vector, as well as treatment methods comprising the polypeptide, nucleic acid, vector, or composition.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: September 20, 2022
    Assignee: The United States of America,as represented by the Secretary, Department of Health and Human Service
    Inventors: John A. Chiorini, Giovanni Di Pasquale, Randy Chandler, Charles P. Venditti
  • Method for generating retinal pigment epithelium (RPE) cells from induced pluripotent stem cells (IPSCs)
    Patent number: 11441184
    Abstract: High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: September 13, 2022
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kapil Bharti, Janine Davis, Arvydas Maminishkis, Sheldon S. Miller
  • Regulatory T cell epitopes
    Patent number: 11441122
    Abstract: The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprise a polypeptide comprising at least a portion of SEQ NOS: 1-14, fragments and/or variants thereof, as well as methods of producing and using the same.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: September 13, 2022
    Assignees: EpiVax Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services Food and Drug Administration
    Inventors: William Martin, Amy S. Rosenberg